Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.

By O. Cornely, J. Maertens, D. Winston, J. Perfect, A. Ullmann, T. Walsh, D. Helfgott, J. Hołowiecki, D. Stockelberg, Y. Goh and 4 more. New England Journal of Medicine, 2007

1,520 citations recorded by the source corpus.

Subfields: Epidemiology, Infectious Diseases, Oncology

View Paper: https://www.semanticscholar.org/paper/8a45ebfc2fa8d8711fe09a2dccebcff5f66d9b87

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. J. Perfect
2. D. Kontoyiannis
3. T. Walsh
4. Thierry Calandra
5. E. Anaissie
6. M. Pfaller
7. D. Diekema

In Infectious Diseases

1. D. Kontoyiannis
2. J. Perfect
3. J. Fishman
4. E. Anaissie
5. M. Pfaller
6. D. Diekema

In Oncology

1. J. Fishman

Citations in the corpus

• Emergence of Azole Resistance in Aspergillus fumigatus and Spread of a Single Resistance Mechanism (2008, neutral): “Recently, another triazole, posaconazole, was reported to be highly effective in preventing invasive aspergillosis in neutropaenic patients with acute myeloid leukaemia and myelodysplastic syndrome and in patients with graft-versushost-disease [3,4].”
• Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America (2009, background): “drome [127], and an open-label study of prophylaxis with cas-”
• Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. (2008, background): “efficacy, in strategy trials [2–6], for the formulation of clinical”
• Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. (2008, background): “A clinical trial of posaconazole therapy has recently been reported that demonstrated its superiority versus fluconazole or itraconazole in prevention of invasive aspergillosis in patients with acute myeloid leukemia and myelodysplasia [105].”
• Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. (2016, background): “ution demonstrated its superiority vs fluconazole or itraconazole in the prevention of IA among patients with AML and MDS undergoing chemotherapy [292].”